Strong Revenue Growth: BeiGene reported a full-year revenue of $3.8 billion for 2024, representing a 55% increase compared to $2.5 billion in 2023. The fourth-quarter revenue was $1.1 billion, showing a 77% year-over-year growth. BRUKINSA sales reached $828 million in Q4 alone, marking a notable 100% growth compared to the same period last year.
Guidance for 2025: The company expects revenue between $4.9 billion and $5.3 billion in 2025, driven by continued share gains for BRUKINSA in the U.S. market and expansion in Europe and other international markets. This is underpinned by a stable pricing environment and momentum from new patient starts, particularly as the company laps 2024's strong performance.
Hematology Franchise Leadership: BeiGene is positioning BRUKINSA as the preferred BTK inhibitor for CLL treatment, capturing over 50% of new patient share and achieving a significant lead in both frontline and relapsed/refractory cases. This success is attributed to BRUKINSA's superior profile compared to competitors like Calquence and IMBRUVICA.